The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
Bibliographical noteFunding Information:
PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries, and the Associations, and Bill & Melinda Gates Foundation. KEK, MMO, and PLH are employees of Sanofi Pasteur. MS, RvdM, ES, and PD are employees of the GlaxoSmithKline group of companies. PD and RvdM report holding shares and restricted shares in GlaxoSmithKline. UH is a member of The Global Pertussis Initiative, which is supported by Sanofi Pasteur. NM and CL hold patents on the use of the live-attenuated BPZE1 vaccine and are members of the Scientific Advisory Board of ILIAD Biotechnologies. PS holds patents on the use of adenylate cyclase toxoid in pertussis vaccines and is founder and shareholder of Revabiotech SE, which develops a next generation of whole cell pertussis vaccine.
© 2019 Elsevier Ltd